For Ardelyx Inc. (ARDX), the first quarter of 2024 heralded the dawn of a new era, with Ibsrela's continued upward trajectory and Xphozah's successful launch, propelling the company into commercial prominence.
Ibsrela, the company's flagship drug, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Although the drug was approved by the FDA in September 2019 itself, it was launched in the U.S. only in April 2022.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.